Zimbabwe roll-out of long-acting HIV prevention drug gets underway
With clinical studies demonstrating near-total protection, lenacapavir has been described by some health officials as a turning point for high-risk groups.
With clinical studies demonstrating near-total protection, lenacapavir has been described by some health officials as a turning point for high-risk groups.
Be the first to comment



